Publications

Publications

2026 28

  1. Translocation of the environmental bacterium Aquitalea magnusonii promotes systemic inflammation and liver fibrosis in chronic liver disease

    Tyc O, Arif S, Uschner FE, …, Bruns T, …, Schierwagen R

    J Hepatol (2026) PubMedDOI

  2. Osteopenia Is Associated with Inferior Survival After Deceased-Donor Liver Transplantation

    Belger E, Palzer J, Roeth AA, …, Bruns T, …, Meister FA

    J Clin Med (2026) PubMedDOI

  3. Single-cell profiling reveals monocyte mitochondrial dysfunction in patients with cirrhosis progressing to acute-on-chronic liver failure

    Wirtz TH, Palomino-Echeverria S, Pollmanns MR, …, Bruns T, …, Gomez-Cabrero D

    JHEP Rep (2026) PubMedDOI

  4. Beyond Prophylaxis: Antimicrobial Stewardship for Bacterial Infections in Cirrhosis

    Haedge F, Mücke MM, Lange CM, Bruns T

    United European Gastroenterol J (2026) PubMedDOIPMC

  5. Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS-AKI

    Schleicher EM, Labenz C, Uschner FE, …, German cirrhosis study group

    Liver Int (2026) PubMedDOIPMC

  6. Bone marrow-derived cells repopulate the human peritoneal cavity after allogeneic stem cell transplantation

    Albesais LS, Rooney M, Quickert S, …, Bruns T, Stengel S

    npj Gut and Liver (2026) DOI

  7. Preoperative C-Reactive Protein-to-Albumin Ratio Predicts Recipient and Graft Survival After Deceased-Donor Liver Transplantation

    Erren D, Meister FA, Große K, Bruns T, Gestels N, Beetz O, Oldhafer F, von Websky MW, Vogel T, Vondran FWR, Amygdalos I

    J Clin Med (2026) PubMedDOIPMC

  8. Encapsulated faecal microbiota transfer to target immune activation in patients with cirrhosis and ascites (TransImmune): protocol for a randomised, double-blind, Phase IIa, placebo-controlled trial

    Große K, Haedge F, Fera C, …, Bruns T

    BMJ Open (2026) PubMedDOIPMC

  9. Decompression of portal hypertension by transjugular intrahepatic portosystemic shunt reverses markers of gut barrier dysfunction and cirrhosis-associated immune dysfunction

    Piecha F*, Al Jawazneh A*, Buescher G, …, Kluwe J*, in Cooperation with the German Cirrhosis Study Group of the DGVS

    Gut (2026) PubMedDOI

  10. S2k guideline Gastrointestinal Bleeding of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) - December 2025 - Version 2.0 - AWMF registration number: 021-028

    für die Autoren des DGVS Leitlinienkomitees/for the authors of the DGVS guideline committee, Autorinnen/Autoren, Collaborators

    Z Gastroenterol (2026) PubMedDOI

  11. Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis

    Incicco S, Patidar KR, Juanola A, …, International Club of Ascites GLOBAL AKI team

    J Hepatol (2026) PubMedDOI

  12. Delphi survey to explore core curriculum for training the next generation of hepatologists

    Xu X, Shi Y, Tacke F, …, Global Hepatology Training Consortium

    JHEP Rep (2026) PubMedDOIPMC

  13. Machine Learning Predicts Hepatocellular Carcinoma Risk from Routine Clinical Data: A Large Population-Based Multicentric Study

    Clusmann J, Koop PH, Zhang DY, …, Bruns T, …, Kather JN*, Schneider CV*

    Cancer Discov (2026) PubMedDOIPMC

  14. Update der S3-Leitlinie „Seltene Lebererkrankungen (LeiSe LebEr) – Autoimmune Lebererkrankungen von der Pädiatrie bis zum Erwachsenenalter“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – Living guideline

    Sebode M, Bantel H, Baumann U, …, Collaborators

    Z Gastroenterol (2026) PubMedDOI

  15. The future of hepatology: Preventing liver disease together with the public, scientists and artificial intelligence

    Laevens BPM, Meeßen C, Pijpers FP, Bruns T, Chen Y, Loomba R, Jakhar N, Arning K, Schneider KM, Schneider CV

    JHEP Rep (2026) PubMedDOIPMC

  16. Letter: Attempted Validation of Villin-1 as a Gut Barrier Marker in Decompensated Cirrhosis-Potential Confounding by Tubular Injury and Aetiology

    Haedge F, Murad M, El-Hassani M, Quickert S, Große K, Reißing J, Frissen M, Reuken PA, Bruns T

    Aliment Pharmacol Ther (2026) PubMedDOI

  17. Elevated Polyreactive Immunoglobulin G in Immune-Mediated Liver Injuries With the Need for Immunosuppressive Therapy

    Kirchner T, Dalekos GN, Zachou K, …, Bruns T, …, pIgG study group

    Liver Int (2026) PubMedDOIPMC

  18. Performance of reMELD-Na as a predictor of short-term mortality in patients with cirrhosis and ascites

    Quickert S, Große K, Grubert ES, Stallmach A, Wirtz TH, Zipprich A, Reuken PA, Bruns T

    JHEP Rep (2026) PubMedDOIPMC

  19. Immune biomarkers predicting response to G-CSF in acute-on-chronic liver failure: results from a GRAFT trial sub-study

    Splith K, Berndt N, Haber PK, …, Bruns T, …, Schmelzle M

    Hepatol Int (2026) PubMedDOIPMC

  20. Comparative performance of ReMELD-Na, MELD 3.0 and established scores after TIPS for refractory ascites: A multicenter study

    Kimmann M, Farouk N, Bettinger D, …, Bruns T, …, German Cirrhosis Study Group

    JHEP Rep (2026) PubMedDOIPMC

  21. Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut-liver crosstalk for clinical translation

    Benedé-Ubieto R, Estévez-Vázquez O, Acar R, …, Bruns T, …, Nevzorova YA

    Gut Microbes (2026) PubMedDOIPMC

  22. Clinical course and prognostic risk factors of SARS-CoV-2 vaccine-related hepatitis: differentiating severe acute respiratory syndrome coronavirus 2 vaccine-associated liver injury from autoimmune hepatitis

    Malino D, Codoni G, Kirchner T, …, Bruns T, …, Terziroli Beretta-Piccoli B

    Eur J Gastroenterol Hepatol (2026) PubMedDOI

  23. Die Darm-Leber-Achse bei Leberzirrhose

    Bruns T, Trebicka J

    Die Gastroenterologie (2026) DOI

  24. Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome-Acute Kidney Injury

    Uschner FE, Schleicher EM, Passenberg M, …, German Cirrhosis Study Group

    Clin Gastroenterol Hepatol (2026) PubMedDOI

  25. Higher prevalence of cytomegalovirus and Epstein-Barr virus in acute-on-chronic liver failure

    Thiyagarajah K, Sonnenberg J, Görgülü E, …, Bruns T, …, Peiffer KH

    JHEP Rep (2026) PubMedDOIPMC

  26. Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis

    Wong YJ, Lam L, Soret PA, …, Bruns T, …, Global & ERN Rare-Liver PBC Study Groups

    J Hepatol (2026) PubMedDOI

  27. Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome

    Ma AT, Juanola A, Patidar KR, …, Bruns T, …, International Club of Ascites GLOBAL AKI team

    Clin Gastroenterol Hepatol (2026) PubMedDOIPMC

  28. Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated Cirrhosis

    Arvaniti P, Rodríguez-Tajes S, Padilla M, …, Bruns T, …, Spanish Registry for Autoimmune and Cholestatic Diseases (ColHai) Registry

    Clin Gastroenterol Hepatol (2026) PubMedDOI

2025 28

  1. Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologies

    Luo J*, Hu M*, Feng T*, Zhang L*, Huang Y*, Huang Y*, Ye F*, Li J*, …, Chinese Group on the Study of Severe Hepatitis B (COSSH)

    Gut (2025) PubMedDOIPMC

  2. [Position paper for the standardized use of transjugular intrahepatic portosystemic shunt (TIPS) in adults]

    Trebicka J, Steib C, Zipprich A, …, Bruns T, …, Rössle M

    Z Gastroenterol (2025) PubMedDOIPMC

  3. Therapeutic plasma exchange in amatoxin associated acute liver failure-results from the multi-center Amanita-PEX study

    Stahl K*, Nalbant B*, Pape T*, …, Bruns T, …, Amanita-PEX-study group

    Crit Care (2025) PubMedDOIPMC

  4. Outbreak of multi-drug resistant Vibrio cholerae Ogawa Serotype in Ibb, Yemen (2018-2024): The OVCO-IY study

    Al-Herwi E, Al-Kainai H, Alshoaibi M, …, Bruns T, …, Begali H

    Int J Infect Dis (2025) PubMedDOI

  5. Circulating extracellular vesicles predict outcome in patient undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement

    Loosen SH*, Hansen FJ*, Schatilow D, …, Bruns T*, Roderburg C*

    Sci Rep (2025) PubMedDOIPMC

  6. Peritoneal immunity in decompensated cirrhosis

    Ibidapo-Obe O, Rooney MD, Bruns T

    Expert Rev Clin Immunol (2025) PubMedDOI

  7. Early implantation of a transjugular intrahepatic portosystemic shunt (TIPS) in patients with liver cirrhosis and ascites (eTIPS): a multicentre, randomised controlled trial

    Bettinger D, Janoschke M, Jenkner C, Kaufmann M, van Gessel J, Otter HH, Schultheiss M, Thimme R, on behalf of the eTIPS study group

    Trials (2025) PubMedDOIPMC

  8. Acute Variceal Bleeding During the SARS-CoV-2 Pandemic: A National Multicenter Observational Study

    Allo G, Quickert S, Große K, Baysal S, Nierhoff D, Neumann-Haefelin C, Schramm C, Bruns T, Reuken PA, Bürger M

    J Clin Med (2025) PubMedDOIPMC

  9. SARS-CoV-2 Antibody Prevalence Across Unvaccinated Health Care Workers During the COVID-19 Pandemic in Yemen: Cross-Sectional Study

    Al-Herwi E, Baras M, Alhetar K, …, Bruns T

    JMIR Public Health Surveill (2025) PubMedDOIPMC

  10. The prognostic significance of HDL-associated apolipoproteins in ascitic fluid from patients with cirrhosis and spontaneous bacterial peritonitis

    Murad M, Reuken PA, Schubert K, Reißing J, Ibidapo-Obe O, Große K, Frissen M, Haedge F, El-Hassani M, von Bergen M, Bruns T

    Sci Rep (2025) PubMedDOIPMC

  11. Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis

    Trebicka J*, Aguilar F*, Queiroz Farias A*, Lozano JJ*, …, PREDICT study and ACLARA study

    Gut (2025) PubMedDOI

  12. S3 guideline "Rare liver diseases (LeiSe LebEr) - Autoimmune liver diseases from paediatrics to adulthood" of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

    Autorinnen/Autoren, Collaborators

    Z Gastroenterol (2025) PubMedDOI

  13. Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut-Vascular Barrier Damage Across Stages of Cirrhosis

    Haedge F, Reuken PA, Reißing J, Große K, Frissen M, El-Hassani M, Aschenbach R, Teichgräber U, Stallmach A, Bruns T

    Liver Int (2025) PubMedDOIPMC

  14. Aszites – Diagnostik, Therapie und aktuelle Herausforderungen

    Große K, Bruns T

    Gastroenterologie up2date (2025) DOI

  15. Transjugular diagnostic procedures in hepatology: Indications, techniques and interpretation

    Bettinger D, Berzigotti A, Mandorfer M, …, Bruns T, …, German (D) – Austrian (A) – Swiss (CH) portal hypertension (DACH-PH) consortium

    JHEP Rep (2025) PubMedDOIPMC

  16. Development of a Question Prompt List for People Living With Primary Biliary Cholangitis: A Delphi Study

    Werner E, van Hooff MCB, Weijsters GHX, …, Global PBC Study Group/ERN RARE-LIVER/Question Prompt List

    Clin Gastroenterol Hepatol (2025) PubMedDOI

  17. Early Occurrence of Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt Insertion is Linked to Impaired Survival: A Multicenter Cohort Study

    Kabelitz MA, Sandmann L, Praktiknjo M, …, Bruns T, …, German Cirrhosis Study Group

    Clin Gastroenterol Hepatol (2025) PubMedDOI

  18. Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study

    Patidar KR, Ma AT, Juanola A, …, Bruns T, …, International Club of Ascites GLOBAL AKI team

    Lancet Gastroenterol Hepatol (2025) PubMedDOI

  19. Macrophage-derived IL-15 imprints peritoneal TRM-like CD8 T cells in cirrhosis and spontaneous bacterial peritonitis

    Ibidapo-Obe O, Stengel S, Frissen M, …, Bruns T

    JHEP Rep (2025) PubMedDOIPMC

  20. Antibiotics in decompensated liver disease - who, when and for how long?

    Haedge F, Bruns T

    Expert Rev Gastroenterol Hepatol (2025) PubMedDOI

  21. Freiburg index of post-TIPS survival (FIPS) identifies patients at risk of further decompensation and ACLF after TIPS

    Sturm L, Schultheiss M, Stöhr F, …, Bruns T, …, German Cirrhosis Study Group of the DGVS

    J Hepatol (2025) PubMedDOI

  22. Leitlinie „Lebertransplantation“

    Aehling NF, Bruns T, Berg T, Trautwein C

    Die Gastroenterologie (2025) DOI

  23. Early Dynamics of Portal Pressure Gradient After TIPS Insertion Predict Mortality

    Reuken PA, Franz A, Wirtz TH, …, Bruns T, …, Zipprich A

    Aliment Pharmacol Ther (2025) PubMedDOIPMC

  24. Targeting protein kinase C-α prolongs survival and restores liver function in sepsis: Evidence from preclinical models

    Xiong L, Beyer D, Liu N, …, Bruns T, …, Press AT

    Pharmacol Res (2025) PubMedDOI

  25. Bakterielle Infektionen

    Bruns T

    Komplikationen der Leberzirrhose (2025) DOI

  26. Aszites und Hyponatriämie

    Bruns T, Große K, Gerbes A, Steib C

    Komplikationen der Leberzirrhose (2025) DOI

  27. Komplikationen der Leberzirrhose: Prävention, Diagnostik und Therapie

    Bruns T, Bettinger D, Trebicka J

    Springer (2025) DOI

  28. Longitudinal Evaluation of Individuals With Severe Alpha-1 Antitrypsin Deficiency (Pi∗ZZ Genotype)

    Fromme M, Payancé A, Mandorfer M, …, Bruns T, …, Strnad P

    Gastroenterology (2025) PubMedDOI

2024 15

  1. The Aachen ACLF ICU score predicts ICU mortality in critically ill patients with acute-on-chronic liver failure

    Pollmanns MR, Kister B, Abu Jhaisha S, …, Bruns T, …, Koch A*, Wirtz TH*

    Sci Rep (2024) PubMedDOIPMC

  2. S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)

    Berg T, Aehling NF, Bruns T, …, Trautwein C

    Z Gastroenterol (2024) PubMedDOI

  3. Leitlinienreport der S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein und Viszeralchirurgie (DGAV)

    Lorenz P, Aehling N, Bruns T, Bechstein W, Becker T, Berg T, Freudenberger P, Trautwein C, Klug L, Lynen Jansen P

    Z Gastroenterol (2024) PubMedDOI

  4. Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis

    Lam L, Soret PA, Lemoinne S, …, Bruns T, …, Global & ERN Rare-Liver PBC Study Groups

    Clin Gastroenterol Hepatol (2024) PubMedDOI

  5. Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis

    Roberts SB, Choi WJ, Worobetz L, …, Bruns T, …, Canadian Network for Autoimmune Liver disease (CaNAL)

    JHEP Rep (2024) PubMedDOIPMC

  6. Akut-auf-chronisches Leberversagen

    Bruns T, Lange C

    Die Gastroenterologie (2024) DOI

  7. Type-I interferon shapes peritoneal immunity in cirrhosis and drives caspase-5-mediated progranulin release upon infection

    Rooney M*, Duduskar SN*, Ghait M, …, Bruns T

    J Hepatol (2024) PubMedDOI

  8. Comorbidities, mortality and metabolic profile in individuals with primary biliary cholangitis-A Phenome-Wide-Association-Study

    Koop PH, Schwenzer C, Clusmann J, Vell MS, Jaeger J, Gui W, Trautwein C, Koch A, Bruns T, Schneider CV, Schneider KM

    Liver Int (2024) PubMedDOI

  9. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

    Dietz J, Graf C, Berg CP, …, Bruns T, …, European HCV Resistance Study Group

    JHEP Rep (2024) PubMedDOIPMC

  10. Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS

    Loosen SH, Benz F, Mohr R, …, Bruns T, …, Roderburg C

    JHEP Rep (2024) PubMedDOIPMC

  11. [The German Guideline on Liver Transplantation by DGVS and DGAV]

    Bruns T*, Aehling N*, Bechstein WO, Becker T, Trautwein C, Berg T

    Dtsch Med Wochenschr (2024) PubMedDOI

  12. Th2 Cell Activation in Chronic Liver Disease Is Driven by Local IL33 and Contributes to IL13-Dependent Fibrogenesis

    Reißing J, Berres M, Strnad P, Wree A, Inzaugarat ME, Trautwein C, Bruns T*, Zimmermann HW*

    Cell Mol Gastroenterol Hepatol (2024) PubMedDOIPMC

  13. Efficient formation and maintenance of humoral and CD4 T-cell immunity targeting the viral capsid in acute-resolving hepatitis E infection

    Csernalabics B, Marinescu MS, Maurer L, …, Bruns T, …, Boettler T

    J Hepatol (2024) PubMedDOI

  14. Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections-Results from the ICA "Global Study" (EABCIR-Global Study)

    Maiwall R, Piano S, Singh V, …, Bruns T, …, International Club of Ascites Global Study Group

    Hepatology (2024) PubMedDOI

  15. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

    Corpechot C, Lemoinne S, Soret PA, …, Bruns T, …, Global & ERN Rare-Liver PBC Study Groups

    Hepatology (2024) PubMedDOI

2023 17

  1. The non-canonical inflammasome activators Caspase-4 and Caspase-5 are differentially regulated during immunosuppression-associated organ damage

    Ghait M, Duduskar SN, Rooney M, Häfner N, Reng L, Göhrig B, Reuken PA, Bloos F, Bauer M, Sponholz C, Bruns T*, Rubio I*

    Front Immunol (2023) PubMedDOIPMC

  2. Early ribavirin for hepatitis E virus infection in patients receiving immunosuppressive therapy: a retrospective, observational study

    Franz A, Reuken PA, Guliyeva S, Rose M, Boden K, Stallmach A, Bruns T

    J Int Med Res (2023) PubMedDOIPMC

  3. Tissue-resident and innate-like T cells in patients with advanced chronic liver disease

    Ibidapo-Obe O, Bruns T

    JHEP Rep (2023) PubMedDOIPMC

  4. Influence of NOD2 risk variants on hepatic encephalopathy and association with inflammation, bacterial translocation and immune activation

    Ripoll C, Greinert R, Reuken P, Reichert MC, Weber SN, Hupfer Y, Staltner R, Meier Clinien M, Lammert F, Bruns T, Zipprich A

    Liver Int (2023) PubMedDOI

  5. An old foe on peculiar paths: severe falciparum malaria in a Syrian refugee, possibly infected during migrant smuggling from Türkiye to Germany

    Brozat JF*, Haverkamp M*, Hohlstein P, Adams JK, Wirtz TH, Klingel HR, Hürtgen S, Hamesch K, Bruns T, Trautwein C, Jhaisha SA*, Koch A*

    Infection (2023) PubMedDOIPMC

  6. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival

    Murillo Perez CF, Ioannou S, Hassanally I, …, Bruns T, …, Global PBC Study Group

    Liver Int (2023) PubMedDOI

  7. Gut-liver axis: barriers and functional circuits

    Pabst O, Hornef MW, Schaap FG, Cerovic V, Clavel T, Bruns T

    Nat Rev Gastroenterol Hepatol (2023) PubMedDOI

  8. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial

    Ripoll C, Platzer S, Franken P, Aschenbach R, Wienke A, Schuhmacher U, Teichgräber U, Stallmach A, Steighardt J, Zipprich A, Liver-HERO Study Group

    Trials (2023) PubMedDOIPMC

  9. Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)

    Weiss E, de la Peña-Ramirez C, Aguilar F, …, Bruns T, …, Arroyo V

    Gut (2023) PubMedDOIPMC

  10. Lack of Cyclin E1 in hepatocytes aggravates ethanol-induced liver injury and hepatic steatosis in experimental murine model of acute and chronic alcohol-associated liver disease

    Ramadori P, Woitok MM, Estévez-Vázquez O, …, Bruns T, …, Nevzorova YA

    Biochim Biophys Acta Mol Basis Dis (2023) PubMedDOI

  11. Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis

    Gurbuz B, Guldiken N, Reuken P, …, Bruns T*, Strnad P*

    Hepatol Int (2023) PubMedDOIPMC

  12. Gastrointestinale Notfälle

    Bürger M, Bruns T, Schramm C

    Klinische Akut- und Notfallmedizin (2023) DOI

  13. Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis

    de Veer RC, van Hooff MC, Corpechot C, …, Bruns T, …, Global PBC Study Group

    Am J Gastroenterol (2023) PubMedDOIPMC

  14. Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe

    Murillo Perez CF, Gerussi A, Trivedi PJ, …, Bruns T, …, GLOBAL PBC Study Group

    Eur J Gastroenterol Hepatol (2023) PubMedDOI

  15. [Use of Thrombopoetin-Receptor-Agonists (TPO-RA) in patients with liver cirrhosis before invasive procedures]

    Mücke MM, Bruns T, Canbay A, Matzdorff A, Tacke F, Tiede A, Trebicka J, Wedemeyer H, Zacharowski K, Zeuzem S, Lange CM

    Z Gastroenterol (2023) PubMedDOI

  16. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination

    Codoni G, Kirchner T, Engel B, …, Bruns T, …, Terziroli Beretta-Piccoli B

    JHEP Rep (2023) PubMedDOIPMC

  17. Splanchnic Vein Thrombosis With Thrombopenia in a Young Otherwise Healthy Patient

    Fromme M, Zimmermann HW, Bruns T

    Gastroenterology (2023) PubMedDOI

2022 14

  1. [Current diagnostics and treatment of portal hypertension]

    Zimmermann HW, Trautwein C, Bruns T

    Inn Med (Heidelb) (2022) PubMedDOI

  2. Clinical and surgical factors for successful stoma reversal in patients with Crohn's disease-results of a retrospective cohort study

    Ludewig C, Jacob V, Stallmach A, Bruns T*, Teich N*

    Int J Colorectal Dis (2022) PubMedDOI

  3. Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid

    de Veer RC, Harms MH, Corpechot C, …, Bruns T, …, Global PBC Study Group

    Aliment Pharmacol Ther (2022) PubMedDOIPMC

  4. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

    Murillo Perez CF, Fisher H, Hiu S, …, Bruns T, …, GLOBAL PBC Study Group and the members of the UK-PBC Consortium

    Gastroenterology (2022) PubMedDOI

  5. Phenome of coeliac disease vs. inflammatory bowel disease

    Kleinjans M*, Schneider CV*, Bruns T, Strnad P

    Sci Rep (2022) PubMedDOIPMC

  6. Gastrointestinal Infections and the Risk of Inflammatory Bowel Disease in Twins and Siblings: Evidence Against the Hygiene Hypothesis

    Teich N, Stallmach A, Bruns T

    Dig Dis Sci (2022) PubMedDOIPMC

  7. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

    Corpechot C, Carrat F, Gaouar F, …, Bruns T, …, Global & ERN Rare-Liver PBC Study Groups

    J Hepatol (2022) PubMedDOI

  8. Soluble mannose receptor CD206 and von Willebrand factor are early biomarkers to identify patients at risk for severe or necrotizing acute pancreatitis

    Reuken PA*, Brozat JF*, Quickert S, …, Koch A*, Bruns T*

    J Intensive Care (2022) PubMedDOIPMC

  9. COVID-19 mortality in cirrhosis is determined by cirrhosis-associated comorbidities and extrahepatic organ failure: Results from the multinational LEOSS registry

    Brozat JF, Hanses F, Haelberger M, …, Bruns T, LEOSS study group

    United European Gastroenterol J (2022) PubMedDOIPMC

  10. [Bacterial hepatobiliary infections : Pathogen spectrum, antimicrobial resistance and current treatment concepts]

    Bruns T, Stallmach A

    Internist (Berl) (2022) PubMedDOI

  11. ROS-Sensitive Polymer Micelles for Selective Degradation in Primary Human Monocytes from Patients with Active IBD

    Gardey E, Sobotta FH, Quickert S, Bruns T, Brendel JC, Stallmach A

    Macromol Biosci (2022) PubMedDOI

  12. Real-World Effectiveness of Piperacillin/Tazobactam with and without Linezolid for Spontaneous Bacterial Peritonitis

    Quickert S, Würstle S, Reuken PA, Hagel S, Schneider J, Schmid RM, Neugebauer S, Stallmach A, Bruns T

    Dig Dis (2022) PubMedDOI

  13. Immunomodulatory receptor VSIG4 is released during spontaneous bacterial peritonitis and predicts short-term mortality

    Reißing J, Lutz P, Frissen M, …, Bruns T

    JHEP Rep (2022) PubMedDOIPMC

  14. Reply to: "G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!"

    Engelmann C, Bruns T, Berg T

    J Hepatol (2022) PubMedDOI

2021 25

  1. A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy

    Guo F, Estévez-Vázquez O, Benedé-Ubieto R, …, Bruns T, …, Nevzorova YA

    Cancers (Basel) (2021) PubMedDOIPMC

  2. Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease

    Chen C, Wu H, Ye H, …, Bruns T, …, Cubero FJ

    Cancers (Basel) (2021) PubMedDOIPMC

  3. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool

    Murillo Perez CF, Gulamhusein A, Carbone M, …, Bruns T, …, GLOBAL PBC Study Group

    Eur J Gastroenterol Hepatol (2021) PubMedDOI

  4. Clinical characteristics and outcome of patients with enterococcal liver abscess

    Große K, Ohm D, Würstle S, Brozat JF, Schmid RM, Trautwein C, Stallmach A, Bruns T, Reuken PA

    Sci Rep (2021) PubMedDOIPMC

  5. Acceptance of SARS-CoV-2 vaccines by liver transplant recipients and candidates

    Reuken PA, Albers S, Rauchfuss F, Strnad P, Settmacher U, Trautwein C, Stallmach A, Bruns T

    Z Gastroenterol (2021) PubMedDOI

  6. Hepatobiliary phenotype of individuals with chronic intestinal disorders

    Voss J*, Schneider CV*, Kleinjans M, Bruns T, Trautwein C, Strnad P

    Sci Rep (2021) PubMedDOIPMC

  7. Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD)

    Estévez-Vázquez O, Benedé-Ubieto R, Guo F, …, Bruns T, …, Nevzorova YA

    Biomedicines (2021) PubMedDOIPMC

  8. Greenspace in Childhood: A New Avenue to Prevent Inflammatory Bowel Disease?

    Teich N, Stallmach A, Bruns T

    Am J Gastroenterol (2021) PubMedDOI

  9. Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)

    Engelmann C, Herber A, Franke A, Bruns T, …, Berg T

    J Hepatol (2021) PubMedDOI

  10. Liver transplantation in malignant disease

    Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP

    World J Clin Oncol (2021) PubMedDOIPMC

  11. Mortality in Patients With Genetic and Environmental Risk of Liver Disease

    Schneider CV, Fromme M, Schneider KM, Bruns T, Strnad P

    Am J Gastroenterol (2021) PubMedDOI

  12. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis

    Goet JC, Murillo Perez CF, Harms MH, …, Bruns T, …, GLOBAL PBC Study Group

    Am J Gastroenterol (2021) PubMedDOI

  13. A Multi-Omics Analysis of Mucosal-Associated-Invariant T Cells Reveals Key Drivers of Distinct Modes of Activation

    Schubert K, Karkossa I, Schor J, Engelmann B, Steinheuer LM, Bruns T, Rolle-Kampczyk U, Hackermüller J, von Bergen M

    Front Immunol (2021) PubMedDOIPMC

  14. Infektionen und Lebertransplantation

    Queck A, Ferstl P, Bruns T, Trebicka J

    Der Gastroenterologe (2021) DOI

  15. Pathogenese und Progression der Leberzirrhose: aktuelle Perspektiven

    Bruns T, Trautwein C

    Der Gastroenterologe (2021) DOI

  16. An Experimental DUAL Model of Advanced Liver Damage

    Benedé-Ubieto R, Estévez-Vázquez O, Guo F, …, Bruns T, …, Nevzorova YA

    Hepatol Commun (2021) PubMedDOIPMC

  17. Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases

    Guldiken N*, Argemi J*, Gurbuz B, …, Bruns T, …, Strnad P

    BMC Med (2021) PubMedDOIPMC

  18. Circulating Bile Acids in Liver Failure Activate TGR5 and Induce Monocyte Dysfunction

    Leonhardt J, Haider RS, Sponholz C, …, Bruns T, …, Heller R

    Cell Mol Gastroenterol Hepatol (2021) PubMedDOIPMC

  19. Drug-induced Acute Pancreatitis: Anecdotal Evidence vs Prospective Evaluation

    Teich N, Bruns T, Stallmach A

    Gastroenterology (2021) PubMedDOI

  20. Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis

    Wirtz TH, Reuken PA, Jansen C, …, Bruns T, Berres ML

    JHEP Rep (2021) PubMedDOIPMC

  21. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

    Trebicka J, Fernandez J, Papp M, …, Bruns T, …, PREDICT STUDY group of the EASL-CLIF CONSORTIUM

    J Hepatol (2021) PubMedDOI

  22. Appendectomy in childhood-did it save my sibling from getting ulcerative colitis?

    Teich N, Bruns T, Stallmach A, German IBD Study Group

    Int J Colorectal Dis (2021) PubMedDOI

  23. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure

    Wong F, Piano S, Singh V, …, Bruns T, …, International Club of Ascites Global Study Group

    J Hepatol (2021) PubMedDOI

  24. Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis

    Gerussi A, Bernasconi DP, O'Donnell SE, …, Bruns T, …, Italian PBC Study Group and the GLOBAL PBC Study Group

    Clin Gastroenterol Hepatol (2021) PubMedDOI

  25. Primed circulating monocytes are a source of IL-1β in patients with cirrhosis and ascites

    Stengel S, Steube A, Köse-Vogel N, Kirchberger-Tolstik T, Deshmukh S, Bruns T

    Gut (2021) PubMedDOI

2020 17

  1. Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases

    Hamesch K, Guldiken N, Aly M, …, Bruns T, …, Strnad P

    BMC Med (2020) PubMedDOIPMC

  2. Vaccine-Preventable Diseases

    Akan H, Bruns T, Pletz MW

    Hematologic Malignancies (2020) DOI

  3. Development and validation of a simple and robust model to predict 30-day mortality in patients with Clostridioides difficile-associated enterocolitis

    Katzer KC, Hagel S, Reuken PA, Bruns T, Stallmach A

    BMJ Open Gastroenterol (2020) PubMedDOIPMC

  4. Aktualisierte Leitlinie "Komplikationen der Leberzirrhose" - Was hat sich verändert?

    Zimmermann HW, Bruns T

    Gastro-News (2020) DOI

  5. Thumb sucking or nail biting in childhood and adolescence is associated with an increased risk of Crohn's disease: results from a large case-control study

    Teich N, Mohl W, Primas C, …, Bruns T, …, German IBD Study Group

    Scand J Gastroenterol (2020) PubMedDOI

  6. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

    Trebicka J, Fernandez J, Papp M, …, Bruns T, …, PREDICT STUDY group of the EASL-CLIF Consortium

    J Hepatol (2020) PubMedDOI

  7. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

    Murillo Perez CF, Harms MH, Lindor KD, …, Bruns T, …, GLOBAL PBC Study Group

    Am J Gastroenterol (2020) PubMedDOI

  8. Die akute Cholangitis

    Koenen M, Zimmermann H, Bruns T

    Verdauungskrankheiten (2020) DOI

  9. Between fear and courage: Attitudes, beliefs, and behavior of liver transplantation recipients and waiting list candidates during the COVID-19 pandemic

    Reuken PA, Rauchfuss F, Albers S, Settmacher U, Trautwein C, Bruns T, Stallmach A

    Am J Transplant (2020) PubMedDOIPMC

  10. SARS-CoV-2 as an extrahepatic precipitator of acute-on-chronic liver failure

    Große K, Kramer M, Trautwein C, Bruns T

    Liver Int (2020) PubMedDOIPMC

  11. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis

    Corpechot C, Chazouillères O, Belnou P, …, Bruns T, …, Global PBC Study Group

    J Hepatol (2020) PubMedDOI

  12. Current challenges and future needs of clinical and endoscopic training in gastroenterology: a European survey

    Maida M, Alrubaiy L, Bokun T, Bruns T, Castro V, China L, Conroy G, Trabulo D, Van Steenkiste C, Voermans RP, Burisch J, Ianiro G

    Endosc Int Open (2020) PubMedDOIPMC

  13. Gastrointestinale Mikrobiota bei Leberzirrhose: pathophysiologische Veränderungen und therapeutische Interventionen

    Bruns T, Stallmach A

    Der Gastroenterologe (2020) DOI

  14. Influence of Core Cross-Linking and Shell Composition of Polymeric Micelles on Immune Response and Their Interaction with Human Monocytes

    Gardey E, Sobotta FH, Hoeppener S, Bruns T, Stallmach A, Brendel JC

    Biomacromolecules (2020) PubMedDOI

  15. Peritoneal Level of CD206 Associates With Mortality and an Inflammatory Macrophage Phenotype in Patients With Decompensated Cirrhosis and Spontaneous Bacterial Peritonitis

    Stengel S*, Quickert S*, Lutz P, …, Bruns T

    Gastroenterology (2020) PubMedDOI

  16. Mucosal-Associated Invariant T Cells Redistribute to the Peritoneal Cavity During Spontaneous Bacterial Peritonitis and Contribute to Peritoneal Inflammation

    Ibidapo-Obe O, Stengel S, Köse-Vogel N, Quickert S, Reuken PA, Busch M, Bauer M, Stallmach A, Bruns T

    Cell Mol Gastroenterol Hepatol (2020) PubMedDOIPMC

  17. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis

    Gatselis NK, Goet JC, Zachou K, …, Bruns T, …, Global Primary Biliary Cholangitis Study Group

    Clin Gastroenterol Hepatol (2020) PubMedDOI

2019 12

  1. Transcriptional Suppression of the NLRP3 Inflammasome and Cytokine Release in Primary Macrophages by Low-Dose Anthracyclines

    Köse-Vogel N, Stengel S, Gardey E, Kirchberger-Tolstik T, Reuken PA, Stallmach A, Bruns T

    Cells (2019) PubMedDOIPMC

  2. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response

    Murillo Perez CF, Hirschfield GM, Corpechot C, …, Bruns T, …, GLOBAL PBC Study Group

    Aliment Pharmacol Ther (2019) PubMedDOI

  3. Extended Infusion of β-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study

    Bartoletti M, Giannella M, Lewis RE, …, Bruns T, …, ESGBIS/BICHROME study group

    Clin Infect Dis (2019) PubMedDOI

  4. The ATG16L1 gene variant rs2241880 (p.T300A) is associated with susceptibility to HCC in patients with cirrhosis

    Reuken PA, Lutz P, Casper M, Al-Herwi E, Stengel S, Spengler U, Stallmach A, Lammert F, Nischalke HD, Bruns T

    Liver Int (2019) PubMedDOI

  5. Nonlinear Multimodal Imaging Characteristics of Early Septic Liver Injury in a Mouse Model of Peritonitis

    Yarbakht M, Pradhan P, Köse-Vogel N, Bae H, Stengel S, Meyer T, Schmitt M, Stallmach A, Popp J, Bocklitz TW, Bruns T

    Anal Chem (2019) PubMedDOI

  6. Genetic Variants in the Promoter Region of the Macrophage Migration Inhibitory Factor are Associated with the Severity of Hepatitis C Virus-Induced Liver Fibrosis

    Wirtz TH, Fischer P, Backhaus C, …, Bruns T, …, Berres ML

    Int J Mol Sci (2019) PubMedDOIPMC

  7. Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)

    Gerbes AL, Labenz J, Appenrodt B, …, Lebertransplantierte Deutschland e. V.

    Z Gastroenterol (2019) PubMedDOI

  8. Acute Hepatitis E is an Underreported Cause of Severe Acute Liver Injury

    Quickert S, Reuken PA, Rose M, Boden K, Bruns T

    Clin Gastroenterol Hepatol (2019) PubMedDOI

  9. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis

    Cheung AC, Lammers WJ, Murillo Perez CF, …, Bruns T, …, Global PBC Study Group

    Clin Gastroenterol Hepatol (2019) PubMedDOI

  10. Short-Term Isocaloric Intake of a Fructose- but not Glucose-Rich Diet Affects Bacterial Endotoxin Concentrations and Markers of Metabolic Health in Normal Weight Healthy Subjects

    Nier A, Brandt A, Rajcic D, Bruns T, Bergheim I

    Mol Nutr Food Res (2019) PubMedDOIPMC

  11. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide

    Piano S, Singh V, Caraceni P, …, International Club of Ascites Global Study Group

    Gastroenterology (2019) PubMedDOI

  12. The detection of the cytomegalovirus DNA in the colonic mucosa of patients with ulcerative colitis is associated with increased long-term risk of proctocolectomy: results from an outpatient IBD clinic

    Schenk W, Klugmann T, Borkenhagen A, Klecker C, Dietel P, Kirschner R, Schneider E, Bruns T, Stallmach A, Teich N

    Int J Colorectal Dis (2019) PubMedDOI

2018 12

  1. Candida albicans β-Glucan Differentiates Human Monocytes Into a Specific Subset of Macrophages

    Leonhardt J, Große S, Marx C, …, Bruns T, …, Heller R

    Front Immunol (2018) PubMedDOIPMC

  2. Acute-on-Chronic Liver Failure

    Lange CM, Bechstein WO, Berg T, Engelmann C, Bruns T, Canbay A, Moreau R, Trebicka J

    Visc Med (2018) PubMedDOIPMC

  3. Induction of innate immune memory via microRNA targeting of chromatin remodelling factors

    Seeley JJ, Baker RG, Mohamed G, Bruns T, Hayden MS, Deshmukh SD, Freedberg DE, Ghosh S

    Nature (2018) PubMedDOIPMC

  4. Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis

    Horn P, von Loeffelholz C, Forkert F, Stengel S, Reuken P, Aschenbach R, Stallmach A, Bruns T

    Sci Rep (2018) PubMedDOIPMC

  5. Pulmonary co-infection with nocardia species and nontuberculous mycobacteria mimicking miliary tuberculosis in a patient with Crohn's disease under combined immunosuppressive therapy

    Weber M, Rüddel J, Bruns T, Pletz MW, Stallmach A

    Z Gastroenterol (2018) PubMedDOI

  6. Microbial Spectrum of Intra-Abdominal Abscesses in Perforating Crohn's Disease: Results from a Prospective German Registry

    Reuken PA, Kruis W, Maaser C, Teich N, Büning J, Preiß JC, Schmelz R, Bruns T, Fichtner-Feigl S, Stallmach A, German IBD Study group [GISG]

    J Crohns Colitis (2018) PubMedDOI

  7. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history

    Murillo Perez CF, Goet JC, Lammers WJ, …, Bruns T, …, GLOBAL PBC Study Group

    Hepatology (2018) PubMedDOI

  8. Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype?

    Teich N, Bruns T, Stallmach A

    Aliment Pharmacol Ther (2018) PubMedDOI

  9. Fungal Infections in Patients With Infected Pancreatic Necrosis and Pseudocysts: Risk Factors and Outcome

    Reuken PA, Albig H, Rödel J, Hocke M, Will U, Stallmach A, Bruns T

    Pancreas (2018) PubMedDOI

  10. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome

    Harms MH, Lammers WJ, Thorburn D, …, Bruns T, …, Global PBC Study Group

    Am J Gastroenterol (2018) PubMedDOI

  11. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients

    Bartoletti M, Giannella M, Lewis R, …, Bruns T, …, ESGBIS/BICHROME Study Group

    Clin Microbiol Infect (2018) PubMedDOI

  12. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner

    Trivedi PJ, Tickle J, Vesterhus MN, …, Bruns T, …, Weston CJ

    Gut (2018) PubMedDOIPMC

2017 9

  1. Acute-on-Chronic Liver Failure with Complicating Pancreatitis After Autochthonous Hepatitis E Infection

    Peter J, Stallmach A, Tannapfel A, Bruns T

    Hepatitis Monthly (2017) DOI

  2. Acid Sphingomyelinase Inhibition Prevents Development of Sepsis Sequelae in the Murine Liver

    Chung HY, Witt CJ, Jbeily N, Hurtado-Oliveros J, Giszas B, Lupp A, Gräler MH, Bruns T, Stallmach A, Gonnert FA, Claus RA

    Sci Rep (2017) PubMedDOIPMC

  3. Impaired Transmigration of Myeloid-Derived Suppressor Cells across Human Sinusoidal Endothelium Is Associated with Decreased Expression of CD13

    Resheq YJ, Menzner AK, Bosch J, …, Bruns T, …, Weston CJ

    J Immunol (2017) PubMedDOI

  4. 19. Infektionen bei Leberzirrhose

    Bruns T

    Gastroenterologische Infektiologie (2017) DOI

  5. Genetic variants of TRAF6 modulate peritoneal immunity and the risk of spontaneous bacterial peritonitis in cirrhosis: A combined prospective-retrospective study

    Mai M, Stengel S, Al-Herwi E, Peter J, Schmidt C, Rubio I, Stallmach A, Bruns T

    Sci Rep (2017) PubMedDOIPMC

  6. Serum metabolic signatures in patients with overt hepatic encephalopathy

    Stengel S, Stallmach A, Richter K, Landrock A, Hampe J, Bruns T

    J Hepatol (2017) PubMedDOI

  7. Risk Factors for Multi-Drug Resistant Pathogens and Failure of Empiric First-Line Therapy in Acute Cholangitis

    Reuken PA, Torres D, Baier M, Löffler B, Lübbert C, Lippmann N, Stallmach A, Bruns T

    PLoS One (2017) PubMedDOIPMC

  8. Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD

    Teich N, Bokemeyer B, Mohl W, Walldorf J, Bruns T, Schmidt C, Stallmach A, German IBD Study Group

    Gut (2017) PubMedDOI

  9. Low serum transferrin correlates with acute-on-chronic organ failure and indicates short-term mortality in decompensated cirrhosis

    Bruns T, Nuraldeen R, Mai M, Stengel S, Zimmermann HW, Yagmur E, Trautwein C, Stallmach A, Strnad P

    Liver Int (2017) PubMedDOI

2016 13

  1. Motivation of patients with inflammatory bowel disease to participate in a clinical trial

    Gehrmann U, Berger U, Teich N, Bruns T, Stallmach A, Weber M

    Z Gastroenterol (2016) PubMedDOI

  2. 8. Mikrobiom und Lebererkrankungen

    Bruns T, Roeb E, Goeser F

    Mikrobiom (2016) DOI

  3. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study

    Stallmach A, Langbein C, Atreya R, Bruns T, …, Schmidt C

    Aliment Pharmacol Ther (2016) PubMedDOI

  4. Letter: the therapeutic potential of targeting CCL25/CCR9 in colonic inflammatory bowel disease - reading between the lines

    Trivedi PJ, Schmidt C, Bruns T

    Aliment Pharmacol Ther (2016) PubMedDOI

  5. [Acute-on-chronic liver failure - new Definition of a complex clinical picture]

    Bruns T, Stallmach A

    Dtsch Med Wochenschr (2016) PubMedDOI

  6. NOD2 Risk Variants and Pathological Bacterial Translocation in Decompensated Cirrhosis

    Bruns T, Reuken PA, Stengel S, Gerber L, Appenrodt B, Schade JH, Lammert F, Zeuzem S, Stallmach A

    Dig Dis Sci (2016) PubMedDOI

  7. Effects of Antibiotics on Gut Microbiota

    Lange K, Buerger M, Stallmach A, Bruns T

    Dig Dis (2016) PubMedDOI

  8. The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection

    Bruns T, Reuken PA, Stengel S, Gerber L, Appenrodt B, Schade JH, Lammert F, Zeuzem S, Stallmach A

    Liver Int (2016) PubMedDOI

  9. Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study

    Vogt A, Reuken PA, Stengel S, Stallmach A, Bruns T

    World J Gastroenterol (2016) PubMedDOIPMC

  10. Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity

    Trivedi PJ, Bruns T, Ward S, Mai M, Schmidt C, Hirschfield GM, Weston CJ, Adams DH

    J Autoimmun (2016) PubMedDOIPMC

  11. Bidirectional transendothelial migration of monocytes across hepatic sinusoidal endothelium shapes monocyte differentiation and regulates the balance between immunity and tolerance in liver

    Zimmermann HW, Bruns T, Weston CJ, Curbishley SM, Liaskou E, Li KK, Resheq YJ, Badenhorst PW, Adams DH

    Hepatology (2016) PubMedDOIPMC

  12. Hepatocellular carcinoma surveillance in hepatitis B virus-infected individuals: Who and how?

    Li KK, Trivedi PJ, Von Heimendahl S, Bruns T, Ward ST, Oo Y, Mutimer D

    Hepatology (2016) PubMedDOI

  13. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

    Trivedi PJ, Lammers WJ, van Buuren HR, …, Global PBC Study Group

    Gut (2016) PubMedDOI

2015 6

  1. Letter: serum vitamin D levels in primary biliary cirrhosis

    Bruns T, Kittler C, Stengel S, Trivedi PJ, Stallmach A

    Aliment Pharmacol Ther (2015) PubMedDOI

  2. Low ascitic fluid protein does not indicate an increased risk for spontaneous bacterial peritonitis in current cohorts

    Bruns T, Lutz P, Stallmach A, Nischalke HD

    J Hepatol (2015) PubMedDOI

  3. CMV infection of human sinusoidal endothelium regulates hepatic T cell recruitment and activation

    Bruns T, Zimmermann HW, Pachnio A, Li KK, Trivedi PJ, Reynolds G, Hubscher S, Stamataki Z, Badenhorst PW, Weston CJ, Moss PA, Adams DH

    J Hepatol (2015) PubMedDOI

  4. The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial

    Casper M, Mengel M, Fuhrmann C, Herrmann E, Appenrodt B, Schiedermaier P, Reichert M, Bruns T, Engelmann C, Grünhage F, Lammert F, INCA trial group

    Trials (2015) PubMedDOIPMC

  5. Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand?

    Klinger-Strobel M, Lautenschläger C, Fischer D, Mainz JG, Bruns T, Tuchscherr L, Pletz MW, Makarewicz O

    Expert Opin Drug Deliv (2015) PubMedDOI

  6. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis

    Reuken PA, Kussmann A, Kiehntopf M, Budde U, Stallmach A, Claus RA, Bruns T

    Liver Int (2015) PubMedDOI

2014 8

  1. External ventricular drain infections: risk factors and outcome

    Hagel S, Bruns T, Pletz MW, Engel C, Kalff R, Ewald C

    Interdiscip Perspect Infect Dis (2014) PubMedDOIPMC

  2. Reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis"

    Trivedi PJ, Bruns T, Li KK, Hirschfield GM

    J Hepatol (2014) PubMedDOI

  3. Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis

    Liaskou E, Jeffery LE, Trivedi PJ, Reynolds GM, Suresh S, Bruns T, Adams DH, Sansom DM, Hirschfield GM

    Gastroenterology (2014) PubMedDOIPMC

  4. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure

    Koch A, Zimmermann HW, Gassler N, …, Bruns T, …, Tacke F

    Liver Int (2014) PubMedDOI

  5. Risk factors and outcome of bacterial infections in cirrhosis

    Bruns T, Zimmermann HW, Stallmach A

    World J Gastroenterol (2014) PubMedDOIPMC

  6. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response

    Trivedi PJ, Bruns T, Cheung A, …, Hirschfield GM

    J Hepatol (2014) PubMedDOI

  7. Reticulocyte count and hemoglobin concentration predict survival in candidates for liver transplantation

    Parker R, Armstrong MJ, Bruns T, …, Ferguson JW

    Transplantation (2014) PubMedDOI

  8. [Spontaneous and secondary bacterial peritonitis in cirrhotic patients with ascites]

    Bruns T, Stallmach A

    Zentralbl Chir (2014) PubMedDOI

2013 5

  1. [Empirical antibiotic therapy in intra-abdomial infections: cases and evidence-based therapeutic recommendations]

    Stallmach A, Hagel S, Bruns T, Pletz M, Eckmann C

    Z Gastroenterol (2013) PubMedDOI

  2. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality

    Zimmermann HW, Reuken PA, Koch A, Bartneck M, Adams DH, Trautwein C, Stallmach A, Tacke F, Bruns T

    J Intern Med (2013) PubMedDOI

  3. Attenuated antigen-specific T cell responses in cirrhosis are accompanied by elevated serum interleukin-10 levels and down-regulation of HLA-DR on monocytes

    Peter J, Frey O, Stallmach A, Bruns T

    BMC Gastroenterol (2013) PubMedDOIPMC

  4. Mortality after urinary tract infections in patients with advanced cirrhosis - Relevance of acute kidney injury and comorbidities

    Reuken PA, Stallmach A, Bruns T

    Liver Int (2013) PubMedDOI

  5. Risk factors for QT interval prolongation owing to acute gastrointestinal haemorrhage in patients with cirrhosis

    Lehmann M, Bruns T, Stallmach A

    Liver Int (2013) PubMedDOI

2012 12

  1. Steroidrefraktäre Colitis ulcerosa: aktuelle Strategien der medikamentösen Therapie

    Bruns T, Stallmach A, Schmidt C

    Verdauungskrankheiten (2012) DOI

  2. Recruitment mechanisms of primary and malignant B cells to the human liver

    Shetty S*, Bruns T*, Weston CJ, …, Adams DH

    Hepatology (2012) PubMedDOI

  3. Mid-regional pro-adrenomedullin (MR-proADM): an even better prognostic biomarker than C-reactive protein to predict short-term survival in patients with decompensated cirrhosis at risk of infection?

    Reuken PA, Kiehntopf M, Stallmach A, Bruns T

    J Hepatol (2012) PubMedDOI

  4. Autoimmune hepatitis in an HIV-infected patient: an intriguing association

    Hagel S, Bruns T, Herrmann A, Tannapfel A, Stallmach A

    Int J STD AIDS (2012) PubMedDOI

  5. Calcineurin inhibitors or anti-TNF-α agents in severe ulcerative colitis: available options and limitations

    Bruns T, Schmidt C, Stallmach A

    Z Gastroenterol (2012) PubMedDOI

  6. Emergence of spontaneous bacterial peritonitis due to enterococci - risk factors and outcome in a 12-year retrospective study

    Reuken PA, Pletz MW, Baier M, Pfister W, Stallmach A, Bruns T

    Aliment Pharmacol Ther (2012) PubMedDOI

  7. [Cut a long story too short: Challenges in clinical research]

    Stallmach A, Hagel S, Bruns T, Bauer M

    Dtsch Med Wochenschr (2012) PubMedDOI

  8. Etiologies and outcomes of acute liver failure in Germany

    Hadem J, Tacke F, Bruns T, …, Acute Liver Failure Study Group Germany

    Clin Gastroenterol Hepatol (2012) PubMedDOI

  9. Guidelines for the quantification of HIV and HCV in small volume whole blood samples

    Bruns T, Steinmetzer K

    Methods Mol Biol (2012) PubMedDOI

  10. Further evidence for the relevance of TLR2 gene variants in spontaneous bacterial peritonitis

    Bruns T, Reuken PA, Fischer J, Berg T, Stallmach A

    J Hepatol (2012) PubMedDOI

  11. Recurrent fever and bacteraemia after endoscopic variceal haemostasis with cyanoacrylate: a case report

    Reuken PA, Bruns T, Zimmer B, Michael A, Brunkhorst FM, Pletz MW, Stallmach A

    Infection (2012) PubMedDOI

  12. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis

    Bruns T, Peter J, Reuken PA, Grabe DH, Schuldes SR, Brenmoehl J, Schölmerich J, Wiest R, Stallmach A

    Liver Int (2012) PubMedDOI

2011 8

  1. NOD2 gene variants and spontaneous bacterial peritonitis: authors’ reply

    Bruns T, Wiest R, Stallmach A

    Liver International (2011) DOI

  2. Homozygous carrier of the NOD2 1007fs frame-shift mutation presenting with refractory community-acquired spontaneous bacterial peritonitis and developing fatal pulmonary mucormycosis: A case report

    Bruns T, Peter J, Hagel S, Pfeifer R, Prinz P, Stallmach A

    Hepatol Res (2011) PubMedDOI

  3. [54-year-old male with hepatic cirrhosis and therapy-associated torsade de pointes tachycardia]

    Lehmann M, Bruns T, Herrmann A, Fritzenwanger M, Stallmach A

    Internist (Berl) (2011) PubMedDOI

  4. Medical and surgical therapy of inflammatory bowel disease in the elderly - prospects and complications

    Stallmach A, Hagel S, Gharbi A, Settmacher U, Hartmann M, Schmidt C, Bruns T

    J Crohns Colitis (2011) PubMedDOI

  5. A confocal view of the intestinal microcirculation in a patient with Crohn disease and portal vein thrombosis

    Hagel S, Bruns T, Stallmach A, Schmidt C

    Endoscopy (2011) PubMedDOI

  6. The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection

    Bruns T, Peter J, Hagel S, Herrmann A, Stallmach A

    Clin Exp Immunol (2011) PubMedDOIPMC

  7. Abnormal glucose tolerance: a predictor of 30-day mortality in patients with decompensated liver cirrhosis

    Hagel S, Bruns T, Herrmann A, Stallmach A, Schmidt C

    Z Gastroenterol (2011) PubMedDOI

  8. Subacute liver failure induced by adalimumab

    Hagel S, Bruns T, Theis B, Herrmann A, Stallmach A

    Int J Clin Pharmacol Ther (2011) PubMedDOI

2010 1

  1. Adverse effects of biologics used for treating IBD

    Stallmach A, Hagel S, Bruns T

    Best Pract Res Clin Gastroenterol (2010) PubMedDOI

2009 5

  1. Cholestatic hepatitis, acute acalculous cholecystitis, and hemolytic anemia: primary Epstein-Barr virus infection under azathioprine

    Hagel S, Bruns T, Kantowski M, Fix P, Seidel T, Stallmach A

    Inflamm Bowel Dis (2009) PubMedDOI

  2. Drug monitoring in inflammatory bowel disease: helpful or dispensable?

    Bruns T, Stallmach A

    Dig Dis (2009) PubMedDOI

  3. Hepatitis C virus RNA quantitation in venous and capillary small-volume whole-blood samples

    Bruns T, Steinmetzer K, Ermantraut E, Stallmach A

    J Clin Microbiol (2009) PubMedDOIPMC

  4. Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction

    Bruns T, Sachse S, Straube E, Assefa S, Herrmann A, Hagel S, Lehmann M, Stallmach A

    Liver Int (2009) PubMedDOI

  5. "Nearly a stairway to heaven"--severe dichromate intoxication in a young man

    Illner N, Gerth J, Pfeiffer R, Bruns T, Wolf G

    Clin Nephrol (2009) PubMedDOI

2007 1

  1. [Dislocated port system. Twisted life]

    Jung C, Bruns T

    MMW Fortschr Med (2007) PubMedDOI

* Equal contribution